Is it necessary to receive the 13-valent pneumococcal polysaccharide conjugate vaccine after one year of age?

Dec 05, 2022 Source: Cainiu Health

Dr. Ma Yan

Introduction

It is usually necessary to receive the 13-valent pneumococcal conjugate vaccine after 1 year of age, but specific recommendations should follow medical advice. The 13-valent pneumococcal conjugate vaccine can prevent infections caused by 13 serotypes of Streptococcus pneumoniae and provides protection against more than 90% of invasive pneumococcal pneumonia, offering effective prevention. It generally protects against invasive diseases caused by these 13 pneumococcal serotypes.

Generally, it is necessary to receive the 13-valent pneumococcal conjugate vaccine after the age of 1 year, according to specific medical advice.

The 13-valent pneumococcal conjugate vaccine can prevent infections caused by 13 serotypes of Streptococcus pneumoniae and protect against over 90% of invasive pneumococcal pneumonia, offering effective protection. Receiving this vaccine typically prevents invasive diseases caused by these 13 pneumococcal serotypes and is primarily used for active immunization. The 13-valent pneumococcal conjugate vaccine helps prevent diseases caused by pathogens including Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, such as pneumonia, meningitis, and sepsis. The vaccine is usually administered at 2, 4, and 6 months of age, with a booster dose given between 1 and 1.5 years of age. Completing the full series of the 13-valent pneumococcal conjugate vaccine generally provides long-lasting immunity.

In addition, since the 13-valent pneumococcal conjugate vaccine is indicated for infants aged 6 weeks to 15 months, eligible infants should receive the vaccine within the recommended timeframe.

Related Articles

View All

What is the difference between the 13-valent pneumococcal vaccine and the 23-valent pneumococcal vaccine?

The differences between the 13-valent pneumococcal vaccine and the 23-valent pneumococcal vaccine include variations in vaccination coverage, technology, target populations, and more. The 13-valent pneumococcal vaccine protects against 13 types of Streptococcus pneumoniae, while the 23-valent pneumococcal vaccine protects against 23 types, offering broader coverage than the 13-valent vaccine. In addition to these differences, the two vaccines also differ in their compositional components.

View Full Answer

When should the 13-valent vaccine be started, in terms of months?

The 13-valent vaccine clinically refers to the 13-valent pneumococcal polysaccharide conjugate vaccine, which can prevent infections caused by 13 types of Streptococcus pneumoniae, including meningitis, bacteremic pneumonia, sepsis, and other diseases. It is generally administered as one dose at 2, 4, and 6 months after birth, followed by booster doses at 12 and 15 months of age. After vaccination, long-lasting protective antibodies are produced in the body.

View Full Answer

How long after receiving the 13-valent vaccine will fever occur?

Fever generally refers to elevated body temperature. The "13-valent vaccine" refers to the 13-valent pneumococcal polysaccharide conjugate vaccine. It is incorrect to assume a specific timeframe for developing fever, as not everyone will experience fever after vaccination. Individual physical conditions vary, leading to different reactions to vaccines; therefore, not all vaccinated individuals will develop fever. If fever does occur, it typically does not last more than 48 hours after vaccination.

View Full Answer

Which site should the 13-valent vaccine be administered?

Clinically, the 13-valent vaccine refers to the 13-valent pneumococcal polysaccharide conjugate vaccine. This vaccine is usually administered into the lateral deltoid muscle of the upper arm or the anterolateral thigh muscle. Injecting the vaccine at these sites helps ensure its optimal effectiveness. Before receiving the 13-valent pneumococcal polysaccharide conjugate vaccine, it is important to inform the doctor about your actual health condition truthfully.

View Full Answer

Can I directly receive the final dose of the 13-valent vaccine?

The term "13-valent" usually refers to the 13-valent pneumococcal polysaccharide conjugate vaccine, which generally cannot be administered as a single final dose without following the complete schedule. The analysis is as follows: The 13-valent pneumococcal polysaccharide conjugate vaccine is typically a preventive vaccine used to protect against invasive diseases caused by 13 types of Streptococcus pneumoniae. It is commonly used to prevent bacteremia, pneumonia, meningitis, and other conditions. The vaccination series is usually administered between 6 weeks and 5 months of age.

View Full Answer

Can I skip the remaining doses after receiving one shot of the 13-valent pneumococcal polysaccharide conjugate vaccine?

The 13-valent pneumococcal polysaccharide conjugate vaccine may be administered as a single dose without completing the subsequent doses, but it is recommended to complete the full series. The 13-valent pneumococcal polysaccharide conjugate vaccine is an inactivated vaccine primarily intended for individuals aged six weeks to five years. Since the complete vaccination schedule consists of four doses, it is acceptable to receive only one dose without continuing with the remaining doses.

View Full Answer

Can people with blepharitis receive the 13-valent pneumococcal vaccine?

Patients with blepharitis can receive the 13-valent pneumococcal vaccine, as there is no direct contraindication between the two conditions. Blepharitis is a localized inflammation of the eyelid margins, whereas the 13-valent pneumococcal vaccine primarily acts on the systemic immune system to prevent infections caused by Streptococcus pneumoniae. Localized inflammation is not an absolute contraindication for vaccination. However, it is important to ensure that the inflammation is not in an acute flare-up phase before vaccination.

View Full Answer

Can the DTaP vaccine and the 13-valent pneumococcal vaccine be administered together?

Individuals with fever, acute illness, a history of severe allergy, or compromised immune function should postpone combined vaccination to avoid worsening symptoms or affecting vaccine response. Additionally, if an individual has previously experienced a serious adverse reaction after receiving any vaccine, they must inform the healthcare provider in advance for evaluation of whether simultaneous vaccination is appropriate.

View Full Answer

Your trusted source for health information and wellness guidance.

Quick Links

Resources

Connect

© 2024 HealthPortal. All rights reserved.